News Image

Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled

Provided By GlobeNewswire

Last update: Jul 15, 2025

Vancouver, Canada, July 15, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the expansion of its Phase I/IIa clinical trial for CMND-100, its proprietary MEAI-based oral treatment candidate for Alcohol Use Disorder (AUD), with the activation of additional site at Johns Hopkins University School of Medicine and the enrollment of the first participant at this clinical site.

Read more at globenewswire.com

CLEARMIND MEDICINE INC

NASDAQ:CMND (7/23/2025, 8:13:13 PM)

After market: 1.13 0 (0%)

1.13

0 (0%)



Find more stocks in the Stock Screener

Follow ChartMill for more